Plain-English translation of NCT06923709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 study testing whether , a water pill that helps your body retain potassium, can slow down the worsening of chronic kidney disease. About 40 people will participate. Researchers want to see if this medication might help protect your kidneys better than current treatments alone.
Chronic kidney disease can get worse over time, especially when there is protein leaking into your urine, which is a sign of kidney damage. This study exists to find out whether this medication might help slow that decline and protect your kidney function.
You likely qualify if…
You likely don't qualify if…
You will take either the medication or a placebo (inactive pill) twice daily for 7 days, then have a 2–3 week break, and then switch to the other treatment for another 7 days. This crossover design lets researchers compare how your kidneys respond to each. You will have screening visits, blood tests to check your kidney function and potassium levels, and urine tests to measure protein.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Denmark